STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because that oh-so familiar routine of Zoom meetings, deadlines, and bustling about has predictably returned. Not surprising…
ImpactNotable 33/100
Why it mattersRule-based estimate: no strong signals; trust 8/10.
RegionsGlobal
Published5 h ago (Mon, 02 Nov 2026 14:22:08 GMT)
Retrievedvia rss
ClassifiedMon, 02 Nov 2026 15:00:43 GMT by heuristic
AuthorEd Silverman